The Alizé Pharma Group is a group of privately held biopharmaceutical
companies specialized in the development of innovative therapeutics for the
treatment of metabolic diseases and cancer.

Alizé Pharma SAS is focused on the AZP-01 program, a family of unacylated
ghrelin analogs for the treatment of type II diabetes, currently generating
proof-of-concept clinical data. The newly created Alizé Pharma II SAS is
dedicated to the development of a recombinant L-asparaginase,
the AZP-02 program, currently at the preclinical stage for the treatment
of acute lymphoblastic leukaemia, and to AZP-03, a new program
in the field of metabolism.